{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Malignancies&page=16", "query": { "condition": "Gastric Malignancies", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1089, "total_pages": 109, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Malignancies&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Malignancies&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:35:56.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004911", "title": "Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Constipation, Impaction, and Bowel Obstruction", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Gastrointestinal Stromal Tumor", "Quality of Life", "Small Intestine Cancer" ], "interventions": [ { "name": "bowel obstruction management", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004911" }, { "nct_id": "NCT06109467", "title": "Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GastroEsophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil + leucovorin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2024-01-12", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109467" }, { "nct_id": "NCT02052778", "title": "A Study of TAS-120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Urothelial Cancer", "Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors", "Primary CNS Tumors", "Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2014-07-21", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2025-03-27", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052778" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophageal Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Ovarian Epithelial Cancer", "Carcinoma Breast Stage IV", "Hormone-refractory Prostate Cancer", "Head and Neck Cancers- Squamous Cell", "Renal Cell Cancer", "Urinary Bladder Neoplasms", "Cervical Cancer", "Endometrial Cancer", "Glioblastoma Multiforme", "Triple Negative Breast Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy (SG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2012-12-17", "completion_date": "2020-08-13", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 12, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01631552" }, { "nct_id": "NCT02563548", "title": "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC", "Gastric Cancer" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2015-10-22", "completion_date": "2019-03-26", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02563548" }, { "nct_id": "NCT00579748", "title": "Optical Coherence Tomography of the Gastrointestinal Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Barrett's Esophagus With or Without Dysplasia", "Patients With Early Esophageal or Gastric Cancer", "Patients With Intestinal Metaplasia of the Stomach" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2005-06", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2021-04-09", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579748" }, { "nct_id": "NCT00899626", "title": "Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Pancreatic Cancer", "Precancerous Condition" ], "interventions": [], "intervention_types": [], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2002-06", "completion_date": "2045-10", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899626" }, { "nct_id": "NCT05363605", "title": "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma", "Bladder Carcinoma", "Susceptible FGFR3 Genetic Alterations", "FGFR3", "FGFR3 Overexpression", "FGFR3 Receptor", "FGFR3 Protein Overexpression", "Ovarian Cancer", "Colorectal Cancer", "Breast Cancer", "Liver Cancer", "Lung Cancer", "Gastric Cancer" ], "interventions": [ { "name": "[225Ac]-FPI-1966", "type": "DRUG" }, { "name": "[111In]-FPI-1967", "type": "DRUG" }, { "name": "vofatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-04-20", "completion_date": "2023-09-08", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 4, "location_summary": "Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363605" }, { "nct_id": "NCT02144051", "title": "Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor" ], "interventions": [ { "name": "AZD5312", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 32, "start_date": "2014-05", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-23T12:35:56.237Z", "location_count": 3, "location_summary": "Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144051" } ] }